CAJ | 학술논문

目的：探讨干细胞移植对缺血性脑卒中患者血清同型半胱氨酸（ homocysteine，Hcy）、C反应蛋白（ C reactive protein， CRP）及脑源性神经生长因子（ brain derived neurotrophic factor，BDNF）含量的影响。方法收集宜昌市第一人民医院收治的缺血性脑卒中患者42例，随机分为实验组和对照组，每组各21例，对照组给予常规治疗，实验组在常规治疗基础上给予自体骨髓间充质干细胞移植治疗，治疗结束后，对所有患者的血清Hcy、CRP、BDNF水平及临床疗效情况进行检测。结果治疗后，与对照组比较，实验组患者的血清Hcy水平较低，差异具有统计学意义（P＜0.05）；实验组患者的血清CRP水平较低（P＜0.05）；实验组患者的BDNF水平较高（P＜0.05）；实验组患者的实验组患者的FIM、ADL、Fugl-Meyer评分较高（P＜0.05）。结论干细胞移植能够显著降低缺血性脑卒中患者血清Hcy、CRP水平，提高血清BDNF含量，提高治疗效果。
목적：탐토간세포이식대결혈성뇌졸중환자혈청동형반광안산（ homocysteine，Hcy）、C반응단백（ C reactive protein， CRP）급뇌원성신경생장인자（ brain derived neurotrophic factor，BDNF）함량적영향。방법수집의창시제일인민의원수치적결혈성뇌졸중환자42례，수궤분위실험조화대조조，매조각21례，대조조급여상규치료，실험조재상규치료기출상급여자체골수간충질간세포이식치료，치료결속후，대소유환자적혈청Hcy、CRP、BDNF수평급림상료효정황진행검측。결과치료후，여대조조비교，실험조환자적혈청Hcy수평교저，차이구유통계학의의（P＜0.05）；실험조환자적혈청CRP수평교저（P＜0.05）；실험조환자적BDNF수평교고（P＜0.05）；실험조환자적실험조환자적FIM、ADL、Fugl-Meyer평분교고（P＜0.05）。결론간세포이식능구현저강저결혈성뇌졸중환자혈청Hcy、CRP수평，제고혈청BDNF함량，제고치료효과。
Objective To analysis the effect of stem cell transplantation on serum homocysteine ( Hcy ) , C reactive protein ( CRP ) and brain derived neurotrophic factor( BDNF) in patients with ischemic stroke.Methods 42 patients who were diagnosed with ischemic stroke in Yichang First People's Hospital were collected.All patients were randomly divided into experimental group and control group, 21 cases in each group.The control group was treated with conventional therapy, and the experimental group was treated with autologous bone marrow mesenchymal stem cell transplantation for treatment on the basis of conventional therapy, after treatment, the serum levels of serum homocysteine, CRP, BDNF and clinical curative effect were detected in all patients.Results After treatment, compared with control group, the serum Hcy level was lower in the experimental group(P<0.05);the serum CRP level was lower in the experimental group (P<0.05); the serum BDNF level was higher in the experimental group (P<0.05); the FIM, ADL and Fugl-Meyer score were higher in the experimental group(P <0.05).Conclusions The stem cell transplantation can significantly reduce the serum Hcy and CRP levels in patients with ischemic stroke, increase the content of BDNF in serum, improve the therapeutic effect, and have a guiding significance for clinical.